A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

NCT01096862 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: peficitinib
DRUG: Placebo

Sponsor

Astellas Pharma Inc